Given the substantial number of open questions surrounding insulin treatment in T2D and the lack of solid scientific evidence to give an answer to all these issues, an expert panel was organized, with the aim of providing practical guidance to clinicians. The gene discussed is INS; the disease is type 2 diabetes mellitus.